In this review, we analyze data from randomized trials in which low molecular weight heparin was compared with unfractionated heparin, both to estimate the treatment effect of low molecular weight heparin in the initial treatment of venous thromboembolism and to evaluate the effect of the varied proportion of included cancer patients (6% to 22.7%) on the incidence of outcome events (recurrence ...

The use of heparin have increased in the last years in hospitalized both as prophylaxis and therapeutic. One of the encounter complications of heparin especially with unfractionated heparin though it can be seen with Low molecular weight heparin is thrombocytopenia which could be transient non immune or more badly the immune mediated type heparin induced thrombocytopenia (HIT). Heparin-induced ...

i t n ercutaneous coronary intervention (PCI) is frequently erformed in patients who received fibrinolytic therapy for cute myocardial infarction (MI). Currently, unfractionated eparin is the most commonly used antithrombin therapy in his situation. However, unfractionated heparin has certain imitations. It has a narrow therapeutic range, monitoring of he activated clotting time is required, an...

Heparin fractions of different molecular weight and with high affinity for antithrombin were studied with respect to their ability to potentiate the inhibition of activated clotting factors by antithrombin. Inhibition of thrombin, Factor IXa and Factor XIa showed similarities in the dependence on the molecular weight of heparin and was found to decrease with decreasing molecular weight. Inactiv...

Heparin is an anticoagulant agent known to have diverse effects on angiogenesis with some reports suggesting that it can induce angiogenesis while a few have indicated of its inhibitory property. Cancer patients treated for venous thromboembolism with low molecular heparin had a better survival than the unfractionated heparin (UFH). Heparin is known to interact with various angiogenic growth fa...

BACKGROUND Unfractionated heparin has been used extensively for the treatment of unstable angina/non-Q wave myocardial infarction but it has several disadvantages. Low-molecular weight heparins are now recommended although they are 3-5 times costlier than unfractionated heparin since they are convinient to administer and do not require activated thromboplastin time monitoring. Whereas enoxapari...